Антагонисты минералокортикоидных рецепторов: сомнительное прошлое и перспективное настоящее
- Авторы: Напалков Д.А.1
-
Учреждения:
- ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
- Выпуск: Том 17, № 5 (2015)
- Страницы: 63-67
- Раздел: Статьи
- URL: https://journals.rcsi.science/2075-1753/article/view/94299
- ID: 94299
Цитировать
Полный текст
Аннотация
В обзорной статье анализируются имеющиеся в литературе данные по применению антагонистов минералокортикоидных рецепторов, представленных на российском рынке, - спиронолактона и эплеренона - при разных нозологиях, включая первичный гиперальдостеронизм, артериальную гипертензию, сердечную недостаточность, инфаркт миокарда, хроническую болезнь почек. Особый акцент сделан на вопросах переносимости и безопасности. Предпринята попытка дифференциального подхода к выбору спиронолактона и эплеренона в разных подгруппах больных.
Полный текст
Открыть статью на сайте журналаОб авторах
Дмитрий Александрович Напалков
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
Email: dminap@mail.ru
д-р мед. наук, проф. каф. факультетской терапии №1 ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
Список литературы
- Tamargo H, Solini A, Ruilope L.M. Comparison of agents that affect aldosterone action. Semin Nephrol 2014; 34: 285-306.
- Messaoudi S, Jaisser F. Aldosterone and the mineralocorticoid receptor. Eur Heart J Suppl 2011; 13: B4-В9.
- Brown N.J. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 2013; 9: 459-69.
- Williams J.S, Williams G.H. 50th anniversary of aldosterone. J Clin Endocrinol Metab 2003; 88: 2364-72.
- Messaoudi S, Azibani F, Delcayre C et al. Aldosterone, mineralocorticoid receptor, and heart failure. Moll Cell Endocrinol 2012; 350: 266-72.
- Bledsoe R.K, Madauss K.P, Holt J.A et al. A ligand - mediated hydrogen bond network required for the activation of the mineralocorticoid receptors. J Biol Chem 2005; 280 (31): 283-93.
- Fagart J, Huyet J, Pinon G.M et al. Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Nat Struct Mol Biol 2005; 12: 554-5.
- Hultman M.L, Krasnoperova N.V, Li S et al. The ligand - dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol Endocrinol 2005; 19: 1460-73.
- Sica D.A. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005; 10: 23-9.
- Garthwaite S.M, Mc Mahon E.G. The evolution of aldosterone antagonists. Moll Cell Endocrinol 2004; 217: 27-31.
- Rossi G.P. A comprehensive review of the clinical aspects of primary aldosteronism. Nat Rev Endocrinol 2011; 7: 485-95.
- Karagiannis A, Tziomalos K, Papageorgiou A et al. Spironolactone vs. eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 2008; 9: 509-15.
- Partharasarathy H.K, Menard J, White W.B et al. A double - blind randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29: 980-90.
- Newton-Cheh C, Guo S.Y, Gona P et al. Clinical and genetic correlates of aldosterone of aldosterone - to - renin ratio and relations to blood pressure in a community sample. Hypertension 2007; 49: 846-56.
- Meneton P, Galan P, Bertrais S et al. High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle - aged Caucasian populations. J Hum Hypertens 2008; 22: 550-8.
- Nishizaka M.K, Zaman M.A, Calhoun D.A. Efficacy of low - dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925-30.
- Chapman N, Dobson J, Wilson S et al. Anglo-Scandinavian Outcomes Trial Investigators. Effects of spironolacton on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839-45.
- Weinberger M.H, White W.B, Ruilope L.M et al. Effects of eplerenone versus losartan in patients with low - renin hypertension. Am Heart J 2005; 150: 426-33.
- Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril and eplerenone/enalapril in patients with essential hypertension and left ventricle hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-8.
- Calhoun D.A, White W.B. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2: 462-8.
- Zannad F, Gattis Stough W, Rossignol P et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence in clinical practice. Eur Heart J 2012; 33: 2782-95.
- Swedberg K, Eneroth P, Kjekshus J et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS trial study Group. Circulation 1990; 82: 1730-6.
- Yancy C.W, Jessup M, Bozkurt B et al. 2013 ACCF/AHA Guideline for the management of heart failure. J Am Coll Card 2013; 62 (16): e147-e239.
- Milliez P, Deangelis N, Rucker-Martin C et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005; 26: 2193-9.
- Beygui F, Labbe J.P, Cayla G et al. Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life - threating ventricular arrhythmia. Int J Cadiol 2013; 167: 73-9.
- Swedberg K, Zannad F, Mc Murray J.J et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Elerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) study. J Am Coll Cardiol 2012; 59: 1598-603.
- Mc Manus F, Mc Innes G.T, Connell J.M. Drug insight: eplerenone, a mineralocorticoid receptor antagonist. Nat Clin Pract Endocrinol Metab 2008; 4: 44-52.
- Epstein M, Williams G.H, Weinberger M et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-51.
- Navaneethan S.D, Nigwekar S.U, Sehgal A.R et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta - analysis. Clin J Am Kidney Dis 2009; 4: 542-51.
- Gulmez S.E, Lassen A.T, Aalykke C et al. Spironolactone use and the risk of upper gastrointestinal bleeding: a population - based case - control study. Br J Clin Pharmacol 2008; 66: 294-99.
- Jeunemaitre X, Chatellier G, Kreft-Jais C et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-5.
- Pitt B, Zannad F, Remme W.J et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
- Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
- Zannad F, Mc Murray J.J, Krum H et al. for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
- Pitt B, Bakris G, Ruilope L.M et al. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118: 1643-50.
- Ezekowitz J.A, Mc Alister F.A. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009; 30: 469-77.
- Eschalier R, Mc Murray J.J, Swedberg K et al. EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalizations And Survival Study in Heart Failure). J Am Coll Cardiol 2013; 62: 1585-93.